NCT07156227 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
Clinical Trials
19 trialsNCT06211335 2026-03-12
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
University of California, Davis
Phase 1 Recruiting
NCT05674396 2026-02-19
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04862455 2026-01-23
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03070366 2025-09-02
OMET
Groupe Oncologie Radiotherapie Tete et Cou
Phase 2 Active not recruiting
NCT03635164 2025-06-27
Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma
University of Colorado, Denver
Phase 1 Completed
NCT04576091 2024-12-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04220775 2024-11-07
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04834349 2023-09-13
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03522584 2023-06-12
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Washington
Phase 1/2 Terminated
NCT02158234 2023-01-19
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02684253 2022-03-10
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01104922 2022-02-14
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
University of Pittsburgh
Phase 2 Completed
NCT04399785 2020-05-22
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC
West China Hospital
Phase 2 Unknown
NCT01344356 2020-04-10
Stereotactic Body Radiotherapy for Head and Neck Tumors
Mercy Research
Phase 4 Completed
NCT02388932 2019-01-24
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
Case Comprehensive Cancer Center
Phase NA Terminated
NCT00851253 2018-01-17
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Boston Medical Center
Phase NA Completed
NCT01586182 2015-09-04
Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma
Dana-Farber Cancer Institute
Phase 1/2 Withdrawn
NCT00738868 2011-05-13
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed